Melanotan I vs Melanotan II — what the differences actually are

Both compounds are synthetic analogs of alpha-MSH, the 13-amino-acid endogenous peptide derived from POMC. Both were developed at the University of Arizona in the 1980s, both were initially characterized in the same lab by the same researchers, and both were tested as potential tools for pharmacological melanogenesis — stimulating the skin to produce melanin. The relationship ends approximately there. From structure through pharmacokinetics through receptor profile through approved use, they are different compounds with different risk-benefit profiles and very different regulatory histories.

Melanotan I, the compound now approved as afamelanotide (Scenesse), is a linear peptide: NDP-alpha-MSH, with two amino acid substitutions that increase stability and binding affinity at MC1R. The substitution of a norleucine for methionine at position 4 and a D-phenylalanine for L-phenylalanine at position 7 are not arbitrary; they substantially reduce enzymatic degradation while increasing receptor binding potency at MC1R specifically. The selectivity matters. MC1R is expressed predominantly in melanocytes at the periphery — in the skin. Activating MC1R drives eumelanin synthesis: the brown-black pigment that provides photoprotection. The desired clinical effect of MT-I is tanning, and MT-I achieves it through the right receptor in the right location.

MT-I also has, by design, a long half-life relative to endogenous alpha-MSH. In the clinical formulation — the Scenesse bioresorbable implant — the compound is released slowly over weeks from a subcutaneous depot, producing a gradual and sustained elevation of blood levels that mirrors the kind of cumulative sun-tanning response the body produces over a season rather than a single intense exposure. This delivery mechanism was developed specifically because the clinical population for EPP needs months-long photoprotection, not acute tanning on demand. The slow release also reduces the peak-level side effects that would be more pronounced with bolus injection. In clinical trials, the most commonly reported adverse events were nausea (at low incidence), headache, and infusion-site reactions. Hyperpigmentation of existing lesions was observed and is considered an expected pharmacological consequence of MC1R stimulation.

Melanotan II is structurally different from the start. It is a cyclic peptide — a seven-amino-acid ring structure with an acetyl group at the N-terminus and an amide at the C-terminus. The cyclization increases lipophilicity relative to linear alpha-MSH analogs, which means MT-II crosses lipid membranes more readily. This is pharmacologically significant because it means MT-II penetrates the blood-brain barrier at meaningful levels. MT-I does not do this to the same extent. The CNS penetration of MT-II is the direct reason it produces central nervous system effects — libido changes, appetite suppression, mood alterations — that MT-I does not substantially produce at clinical doses.

The receptor profile of MT-II reflects its broader activity. MT-II binds MC1R with potency comparable to MT-I and produces tanning. But it also binds MC3R and MC4R centrally, which drives appetite suppression and the sexual arousal effects documented in the original self-experimentation. It binds MC5R in exocrine tissues. There is no receptor subtype selectivity engineered into MT-II in the way it was engineered into afamelanotide. This was not an oversight in the original research — it was the design intent for a broadly-acting research probe. But it means that when MT-II is used at doses sufficient to produce visible tanning, it is simultaneously acting on central systems in ways that are difficult to control, predict, or disentangle.

The half-life difference is also practically significant. MT-II, administered as a subcutaneous injection, has a half-life on the order of several hours to a day depending on dose and individual metabolism. This means that people who use MT-II for tanning purposes typically need to inject frequently — multiple times per week during a "loading phase" to build up sufficient melanin, then periodically during a "maintenance phase." Each injection produces a peak exposure of the compound across all melanocortin receptors, including the central ones. This pharmacokinetic profile is associated with the acute side effects that MT-II users commonly report: nausea, flushing, spontaneous erections in men, and facial flushing. These are peak-level effects and tend to be most pronounced in the first few weeks of use, though their severity varies substantially between individuals.

The regulatory trajectories could not be more different. MT-I (afamelanotide) has full EMA approval and conditional FDA approval, both specifically for erythropoietic protoporphyria. It is prescribed by physicians, dispensed by specialty pharmacies, administered in clinical settings, and post-marketed with ongoing safety monitoring. The clinical trial program that supported its approval included hundreds of patients and multiple randomized controlled trials. The long-term safety data from the EPP population represents the most rigorous evidence available for any melanocortin peptide in humans.

MT-II has no regulatory approval anywhere in the world for any human use. It has no approved veterinary use. No completed randomized controlled trial has been published demonstrating its safety or efficacy for any indication. The entire body of human-use evidence comes from case reports, adverse event reports to regulatory agencies, and community-generated anecdote. The FDA has issued warnings about unlicensed Melanotan products. The UK's MHRA has done the same, repeatedly. Australian health authorities have published consumer advisories. The consistent message from regulatory bodies is that MT-II is not approved, has not been shown safe for human use in formal studies, and should not be used. That message has had limited impact on the consumer market.

The buyer who cannot distinguish MT-I from MT-II from product labeling — which is, in practice, most buyers in the gray-market supply chain — faces a specific problem. Products labeled "Melanotan" or "MT-1" or "MT-2" in the unlicensed peptide market are not pharmaceutical-grade formulations with verified composition, purity, or dose. They may contain what the label says. They may not. MT-II is more commonly encountered than MT-I in this supply chain, partly because it is cheaper to synthesize and more widely available from the same manufacturing infrastructure that supplies other research peptides, and partly because its broader receptor activity makes it more immediately noticeable to users. People feel MT-II. The nausea and libido effects are signals that something is active, and for some users this reinforces the perception that it is more potent and therefore more valuable.

But "more noticeable" and "safer" are different things, and in the case of MT-I versus MT-II, the compound with the dramatic central effects is also the compound with no approved use, no long-term safety data, a case report literature that includes concerning dermatological findings, and a receptor profile that produces simultaneous changes across multiple organ systems in ways that cannot be fully predicted. MT-I, which produces none of the acute central effects, is the one with 35 years of pharmaceutical development behind it and an approved clinical program.

That inversion — the compound that feels like less is doing more responsible science — is worth sitting with.